Drug Profile
rSIFN-co
Alternative Names: Crystalline recombinant interferon; Recombinant super compound interferon; Recombinant super interferon compoundLatest Information Update: 31 Aug 2022
Price :
$50
*
At a glance
- Originator Sichuan Huiyang Life Science and Technology Corporation
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon-alpha replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II COVID 2019 infections
- Phase I Solid tumours
Most Recent Events
- 08 Aug 2022 rSIFN-co is still in phase-I trial in Solid tumours (Late-stage disease) in USA (SC) (NCT02464007)
- 01 Jul 2022 Phase-I/II clinical trials in COVID-2019 infections (Prevention) in Philippines (Intranasal) (NCT05485584)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Singapore (SC, Injection)